retatrutide weight loss clinical trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Lilly's triple agonist, retatrutide, delivered

That's a favorable outcome compared to being charged for a service you can't receive

Medicaid Spending on GLP-1 Drugs by State Data Source: IRIS by Real Chemistry | Image Credit: Real Chemistry Nationally, Medicaid spending on GLP-1s totaled $3.5 billion between November 2023 and October 2024, averaging $48 per Medicaid enrollee

Waring WS, Webb DJ, Maxwell SR

Their eggs looked like young eggs

The separate but closely related regulatory side is the FDA compounding enforcement wave that hit just before the suit

Gut dysbiosis can lead to a buildup of ammonia, which has been tied to brain fog, trouble staying asleep, and frequent night wakings